Ruchita Balasubramanian1, Parastu Kasaie1, Melissa Schnure1, David W Dowdy1, Maunank Shah2, Anthony Todd Fojo3. 1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. 2. Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD; and. 3. Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Abstract
BACKGROUND: Pre-exposure prophylaxis (PrEP) is a key component in helping to reduce HIV incidence in the United States. Long-acting injectable (LAI) PrEP is a new alternative to oral PrEP; its potential to affect local HIV epidemics remains unclear. METHODS: The Johns Hopkins HIV Economic Epidemiological model (JHEEM) is a dynamic model of HIV transmission in 32 US urban areas. We used JHEEM to project the HIV incidence among men who have sex with men (MSM) from 2020 to 2030 under a range of interventions aimed at increasing PrEP use. RESULTS: In the absence of any intervention (ie, current levels of oral PrEP and HIV care engagement), we projected a 19% reduction (95% credible interval, CrI 1% to 36%) in HIV incidence among MSM from 2020 to 2030 across all 32 cities. Adding 10% LAI PrEP uptake (above a base case of all oral PrEP) reduced the incidence by 36% (95% CrI 23% to 50%) by year 2030. This effect varied between cities, ranging from 22% in Atlanta to 51% in San Francisco. At 25% additional LAI PrEP uptake, this incidence reduction increased to 54% (95% CrI 45% to 64%). Reductions in incidence after introducing LAI PrEP were driven primarily by increased uptake and sustained usage rather than increased efficacy. CONCLUSIONS: LAI PrEP has the potential to substantially reduce HIV incidence among MSM, particularly if it increases PrEP uptake and continued use beyond existing levels. Because potential effects vary by city, the effectiveness of expanding PrEP use is dependent on local dynamics.
BACKGROUND: Pre-exposure prophylaxis (PrEP) is a key component in helping to reduce HIV incidence in the United States. Long-acting injectable (LAI) PrEP is a new alternative to oral PrEP; its potential to affect local HIV epidemics remains unclear. METHODS: The Johns Hopkins HIV Economic Epidemiological model (JHEEM) is a dynamic model of HIV transmission in 32 US urban areas. We used JHEEM to project the HIV incidence among men who have sex with men (MSM) from 2020 to 2030 under a range of interventions aimed at increasing PrEP use. RESULTS: In the absence of any intervention (ie, current levels of oral PrEP and HIV care engagement), we projected a 19% reduction (95% credible interval, CrI 1% to 36%) in HIV incidence among MSM from 2020 to 2030 across all 32 cities. Adding 10% LAI PrEP uptake (above a base case of all oral PrEP) reduced the incidence by 36% (95% CrI 23% to 50%) by year 2030. This effect varied between cities, ranging from 22% in Atlanta to 51% in San Francisco. At 25% additional LAI PrEP uptake, this incidence reduction increased to 54% (95% CrI 45% to 64%). Reductions in incidence after introducing LAI PrEP were driven primarily by increased uptake and sustained usage rather than increased efficacy. CONCLUSIONS: LAI PrEP has the potential to substantially reduce HIV incidence among MSM, particularly if it increases PrEP uptake and continued use beyond existing levels. Because potential effects vary by city, the effectiveness of expanding PrEP use is dependent on local dynamics.
Authors: Kevin M Maloney; Adrien Le Guillou; Robert A Driggers; Supriya Sarkar; Emeli J Anderson; Amyn A Malik; Samuel M Jenness Journal: J Infect Dis Date: 2021-01-04 Impact factor: 5.226
Authors: Anthony Todd Fojo; Melissa Schnure; Parastu Kasaie; David W Dowdy; Maunank Shah Journal: Ann Intern Med Date: 2021-09-21 Impact factor: 25.391
Authors: Raphael J Landovitz; Deborah Donnell; Meredith E Clement; Brett Hanscom; Leslie Cottle; Lara Coelho; Robinson Cabello; Suwat Chariyalertsak; Eileen F Dunne; Ian Frank; Jorge A Gallardo-Cartagena; Aditya H Gaur; Pedro Gonzales; Ha V Tran; Juan C Hinojosa; Esper G Kallas; Colleen F Kelley; Marcelo H Losso; J Valdez Madruga; Keren Middelkoop; Nittaya Phanuphak; Breno Santos; Omar Sued; Javier Valencia Huamaní; Edgar T Overton; Shobha Swaminathan; Carlos Del Rio; Roy M Gulick; Paul Richardson; Philip Sullivan; Estelle Piwowar-Manning; Mark Marzinke; Craig Hendrix; Maoji Li; Zhe Wang; Jeanne Marrazzo; Eric Daar; Aida Asmelash; Todd T Brown; Peter Anderson; Susan H Eshleman; Marcus Bryan; Cheryl Blanchette; Jonathan Lucas; Christina Psaros; Steven Safren; Jeremy Sugarman; Hyman Scott; Joseph J Eron; Sheldon D Fields; Nirupama D Sista; Kailazarid Gomez-Feliciano; Andrea Jennings; Ryan M Kofron; Timothy H Holtz; Katherine Shin; James F Rooney; Kimberly Y Smith; William Spreen; David Margolis; Alex Rinehart; Adeola Adeyeye; Myron S Cohen; Marybeth McCauley; Beatriz Grinsztejn Journal: N Engl J Med Date: 2021-08-12 Impact factor: 176.079
Authors: Julia Raifman; Lorraine T Dean; Madeline C Montgomery; Alexi Almonte; Renata Arrington-Sanders; Michael D Stein; Amy S Nunn; Collette D Sosnowy; Philip A Chan Journal: AIDS Behav Date: 2019-10
Authors: Sheena McCormack; David T Dunn; Monica Desai; David I Dolling; Mitzy Gafos; Richard Gilson; Ann K Sullivan; Amanda Clarke; Iain Reeves; Gabriel Schembri; Nicola Mackie; Christine Bowman; Charles J Lacey; Vanessa Apea; Michael Brady; Julie Fox; Stephen Taylor; Simone Antonucci; Saye H Khoo; James Rooney; Anthony Nardone; Martin Fisher; Alan McOwan; Andrew N Phillips; Anne M Johnson; Brian Gazzard; Owen N Gill Journal: Lancet Date: 2015-09-09 Impact factor: 79.321